- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Deferred PCI equally safe whether treatment decision based on IVUS or FFR: Study
Korea: Deferral of percutaneous coronary intervention (PCI) based on intravascular ultrasound (IVUS) guided treatment decision showed a comparable risk of clinical events with fractional flow reserve (FFR)-guided treatment decision in patients with intermediate coronary artery stenosis, a recent study has shown.
Findings from the post-hoc analysis of 2-year data from the FLAVOUR trial were presented at the 2022 American College of Cardiology meeting and subsequently published online in Circulation: Cardiovascular Interventions.
In real-world practice, operators sometimes use IVUS in this way for left main lesions. However, FFR is considered a gold standard for treatment decision-making for most non-left main lesions, and this remains the case following FLAVOUR.
There is a continued accruing of positive data showing the benefits of intravascular imaging over angiography as a way to optimize stent placement. Still, controversy remains about whether these tools are warranted in all cases. Joo Myung Lee, Sungkyunkwan University School of Medicine, Seoul, Korea, and colleagues sought to compare the prognosis between deferred lesions based on IVUS and FFR-guided treatment decisions.
The researchers conducted a post hoc analysis of the FLAVOUR randomized trial that compared 2-year clinical outcomes between IVUS- and FFR-guided treatment decisions on intermediate coronary artery lesions using predefined criteria. In both the FFR and IVUS groups, vessels were classified into deferred or revascularized vessels, and patients were classified as those with or without deferred lesions.
Vessel-oriented composite outcomes (target vessel revascularization, target vessel myocardial infarction, or cardiac death) in deferred vessels and patient-oriented composite outcomes (myocardial infarction, death, or any revascularization) in patients with deferred lesions were compared between the IVUS and FFR groups.
The researchers reported the following findings:
- A total of 1682 patients and 1820 vessels were analyzed, of which 922 patients and 989 vessels were deferred.
- At 2 years, there was no difference in the cumulative incidence of vessel-oriented composite outcomes in deferred vessels between IVUS (n=375) and FFR (n=614) groups (3.8% versus 4.1%; hazard ratio, 0.91).
- The risk of vessel-oriented composite outcomes was comparable between deferred and revascularized vessels following treatment decision by IVUS (3.8% versus 3.5%; hazard ratio, 1.09) and FFR (4.1% versus 3.6%; hazard ratio, 1.14).
- In the comparison of patient-oriented composite outcomes in patients with deferred lesions, there was no significant difference between the IVUS (n=357) and FFR (n=565) groups (6.2% versus 5.9%; hazard ratio, 1.05).
"Patients whose PCI is deferred do equally well whether that’s a decision based on fractional flow reserve or intravascular ultrasound," the researchers concluded.
The researchers suggest that FFR for treatment decision-making and IVUS for procedural optimization would be the best strategy for PCI. However, IVUS use for treatment decision-making and procedural optimization may be an alternative, especially cost-wise.
Reference:
Lee JM, Kim H, Hong D, Hwang D, Zhang J, Hu X, Jiang J, Nam CW, Doh JH, Lee BK, Kim W, Huang J, Jiang F, Zhou H, Chen P, Tang L, Jiang W, Chen X, He W, Kang J, Ahn SG, Yoon MH, Kim U, Ki YJ, Shin ES, Choi KH, Park TK, Yang JH, Song YB, Choi SH, Gwon HC, Koo BK, Kim HS, Tahk SJ, Wang J, Hahn JY; FLAVOUR Investigators. Clinical Outcomes of Deferred Lesions by IVUS Versus FFR-Guided Treatment Decision. Circ Cardiovasc Interv. 2023 Nov 29:e013308. doi: 10.1161/CIRCINTERVENTIONS.123.013308. Epub ahead of print. PMID: 38018840.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751